eligibility_summary
Inclusion: consent, ≥18, operable stage III or high‑risk stage II colon cancer ≥12 cm from anal verge and above peritoneal reflection, FFPE tumor available, ECOG 0–1, normal labs, WOCBP: negative test + effective contraception. Exclusion: other cancer unless ≥5y remission (except CIS/skin), residual/metastatic disease, recent investigational tx, pregnancy, lactation, or no contraception, IBD/autoimmune, neuropathy >G1 or severe allergy, HIV/HBV/HCV/TB, IMP contraindication, prior neoadjuvant therapy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06490536 (SAGITTARIUS) is a phase III, ctDNA-guided adjuvant trial in operable stage III/high‑risk stage II colon cancer. Interventions and mechanisms: • Chemotherapy: CAPOX and FOLFOX (capecitabine/5‑FU, pyrimidine antimetabolites inhibiting thymidylate synthase, leucovorin potentiates 5‑FU, oxaliplatin, platinum DNA cross‑linker). FOLFIRI (irinotecan, topoisomerase I inhibitor + 5‑FU/LV). TEMIRI (temozolomide, DNA alkylator + irinotecan). • Immunotherapy: nivolumab (anti–PD‑1 mAb) + ipilimumab (anti–CTLA‑4 mAb) to reactivate T cells. • Targeted therapy: trastuzumab + pertuzumab (anti‑HER2 mAbs) and panitumumab (anti‑EGFR mAb). Target cells/pathways: ctDNA‑defined MRD tumor cells, DNA synthesis/repair (TS, TOP1, crosslinks), immune checkpoints on T cells (PD‑1, CTLA‑4), especially MSI‑H/MMRd or POLE/TMB‑high, EGFR/MAPK in MSS RAS/RAF wild‑type, HER2/ERBB in HER2‑amplified tumors. Stratification by MSI/MMR, RAS/RAF, HER2 guides therapy.